19 Jul Kiio, DoD to Collaborate on Musculoskeletal Disease Treatment Project
Today Kiio Inc. announced the enrollment of the first human subjects in the company’s $1.3 million multi-year, multi-institutional Department of Defense project to develop and validate a novel protocol to assist treatment and risk assessment for chronic tendinopathy.
“Our goal is to provide a fast, cost-effective, portable protocol to inform treatment, determination of work-readiness, and prediction of injury for Servicemembers as well as the general population,” Kiio CEO David Grandin said.“We are honored to be working with a stellar team of collaborators, and look forward to making a substantive contribution to an issue that places a tremendous burden on our military in terms of cost, productivity, and quality of life.”
The technology combines Kiio’s clinically validated force sensor (Kiio Sensor®) with a software application which automatically guides administration of the protocol and calculates and compiles complex muscle performance metrics.
Sorry, the comment form is closed at this time.